Allogene Therapeutics Azioni (NASDAQ: ALLO)

Ultime notizie per Allogene Therapeutics (NASDAQ:ALLO) Azioni

Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics Inc

ALLON THERAPEUTICS INC by Allon Therapeutics Inc.

AlloVir Inc

Allot Ltd

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and raises the price target from $27 to $40.

News

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Raises Price Target to $40

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $23 to $17.

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $17

On Tuesday, PTC Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42201952/ptc-therapeutics-announces-topline-results-of-cardinals-trial-of-utreloxastat-in-als-patients" rel="noreferrer noopener">lateral sclerosis patients</a>.
The study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41984686/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with-direct-administration-in-brain" rel="noreferrer noopener">FDA Grants Conditional Approval For PTC Therapeutics&#8217; Gene Therapy As First Ever With Direct Administration In Brain</a>
While modest numerical benefit was recorded on the primary endpoint, and a favorable clinical effect was correlated with lowering plasma neurofilament light chain (NfL), a biomarker of neuronal damage, statistical significance was not achieved (p= 0.52). In addition, significance was not achieved on the secondary efficacy endpoints.
Amyotrophic lateral sclerosis (ALS), sometimes referred to as motor neuron disease or&nbsp;Lou Gehrig&#8217;s&nbsp;disease, is a rare neurodegenerative disease that affects motor neurons in the brain and spinal cord.
Utreloxastat was demonstrated to be safe and well-tolerated in the CardinALS trial. However, further development is not planned due to the lack of efficacy and biomarker signal.
William Blair notes that while the CardinALS trial results were disappointing, the program was not a major factor in its investment thesis. As a result, ending the program does not affect the firm&#8217;s Outperform <a target="_blank" href="https://www.benzinga.com/quote/PTCT/analyst-ratings" rel="noreferrer noopener">rating on the stock</a>.
The analyst highlights the potential approval and launch of sepiapterin as a key growth driver over the next year, particularly in treating Phenylketonuria (PKU). William Blair believes the market is undervaluing this opportunity, with a PDUFA decision expected in July.
The analyst also points to growing investor interest in the company&#8217;s Huntington&#8217;s disease program. Given the strong commercial prospects of this small-molecule therapy, positive discussions with regulators about an accelerated approval pathway for PTC-518 could significantly boost the stock. A Type C meeting with the FDA is planned for the fourth quarter to discuss the regulatory pathway.
Additionally, the company aims to file a U.S. marketing application for vatiquinone in Friedreich&#8217;s ataxia (FA) by late 2024. William Blair expects approval based on the drug&#8217;s clinical data and the FDA&#8217;s recent neurology approvals, especially as no treatments exist for pediatric FA patients.
On Wednesday, PTC Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42210840/ptc-therapeutics-enters-into-agreement-to-sell-priority-review-voucher-for-150-million" rel="noreferrer noopener">for $150 million</a>.
PTC was granted the voucher along with the FDA approval of Kebilidi (eladocagene exuparvovec-tneq) for children and adults <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41984686/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with-direct-administration-in-brain" rel="noreferrer noopener">with AADC deficiency</a>.
Price Action: PTCT stock is down 1.98% at $45.10 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42210794/frontlines-strong-q3-revenue-growth-offset-by-seasonal-tanker-headwinds-and-geopolitical-challenges" target="_blank" rel="noreferrer noopener">Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Biotech

Equities

Health Care

Reiteration

Trading Ideas

General

PTCT

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Guggenheim analyst Shahriar Pourreza maintains New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) with a Neutral and raises the price target from $46 to $49.

Guggenheim Maintains Neutral on New Jersey Resources, Raises Price Target to $49

Northland Capital Markets analyst Mike Grondahl maintains MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with a Outperform and raises the price target from $80 to $100.

Northland Capital Markets Maintains Outperform on MoneyLion, Raises Price Target to $100

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and lowers the price target from $21 to $18.

Telsey Advisory Group Maintains Market Perform on Guess, Lowers Price Target to $18

Guggenheim analyst Robert Drbul maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Buy and lowers the price target from $26 to $25.

Guggenheim Maintains Buy on Kohl's, Lowers Price Target to $25

Telsey Advisory Group analyst Dana Telsey maintains Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) with a Market Perform and raises the price target from $24 to $26.

Telsey Advisory Group Maintains Market Perform on Nordstrom, Raises Price Target to $26

Northland Capital Markets analyst Gus Richard reiterates Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Outperform and raises the price target from $75 to $95.

AMBA

Northland Capital Markets Reiterates Outperform on Ambarella, Raises Price Target to $95

During President-elect Trump's first term, U.S. scrap metal recyclers benefited significantly from the administration's trade policies – tariffs materially increased the cost of imported steel, leading to significant increases in the prices of domestic recycled metals. As&nbsp;Sims Limited's recent $220 million acquisition of Baltimore Steel(1) demonstrated, industry leaders place significant value in scrap metal operators with proprietary supply channels, seasoned leadership, and established operations.

GWAV

Greenwave Technology Solutions Says That It Expects Tariffs On U.S. Steel Imports Will Drive The Company's Revenue Growth And Margin Expansion Throughout Fiscal Year 2025

Telsey Advisory Group analyst Dana Telsey maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and raises the price target from $310 to $320.

BURL

Telsey Advisory Group Maintains Outperform on Burlington Stores, Raises Price Target to $320

FY Financial 2024 Update(1):
Preliminary unaudited FY 2024 revenue is estimated at US$44.6 million(1)
Margins for FY2024 is estimated at approximately 31%
Expected operating profit and improved Adjusted EBITDA(2) for FY2024
FY Financial 2025 Preview:
The Company anticipates strong growth into FY2025 with estimated revenues to exceed $60 million driven by renewed demand from the Company's largest end users of material handling batteries.
This guidance was prepared by taking into account the Company's existing purchase orders, along with anticipated pipeline from its key end users and OEM customers. This guidance also takes into consideration a percentage of anticipated revenue that potentially may be deferred to FY 2026.

ELVA

Electrovaya Expects $45M FY24 Revenue ($45.06M Est.) With 31% Margin; Anticipates $60M+ FY25 Revenues Amid Jamestown Expansion And New Markets

Northland Capital Markets analyst Nehal Chokshi reiterates Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Market Perform and raises the price target from $74 to $77.

NTNX

Northland Capital Markets Reiterates Market Perform on Nutanix, Raises Price Target to $77

Guggenheim analyst Seamus Fernandez maintains Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy and raises the price target from $95 to $110.

APGE

Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $110

Telsey Advisory Group analyst Dana Telsey maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Market Perform and raises the price target from $44 to $46.

URBN

Telsey Advisory Group Maintains Market Perform on Urban Outfitters, Raises Price Target to $46

WIIM

CRWD

Crowdstrke Holdings shares are trading lower after the company reported Q3 fiancial results. HSBC downgraded the stock from Buy to Hold and announced a $347 price target.

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and maintains $450 price target.

ULTA

Telsey Advisory Group Maintains Outperform on Ulta Beauty, Maintains $450 Price Target

SNEX

Stonex Financial Says Its Unit Stonex Group Has Been Awarded General Clearing Member (GCM) Status By European Commodity Clearing AG

ADSK

Autodesk shares are trading lower. The company reported Q3 financial results

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading higher in the<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> premarket session on Wednesday.</a>
The EV manufacturer reportedly prepares to open its first Nio House in the United Arab Emirates (UAE) on November 28, <a target="_blank" href="https://cnevpost.com/2024/11/27/nio-to-open-1st-nio-house-uae-nov-28/" rel="noreferrer noopener">reported</a> CnEV Post. This marks NIO&#8217;s entry into the Middle East and North Africa (MENA) market.
CEO William Li shared the news in a Weibo video, revealing he is on his way to Abu Dhabi for the opening event. The Abu Dhabi Nio House, already conducting sales and deliveries, is NIO&#8217;s flagship showroom concept, featuring a two-story layout with a vehicle display area and an exclusive space for Nio owners.
NIO&#8217;s vehicles are currently available in five European markets: Norway, Germany, the Netherlands, Sweden, and Denmark, the report read.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 40% in the past year. Investors can gain exposure to the stock via Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns" rel="noreferrer noopener">Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs ‘As A Weapon'</a>
This week, Goldman Sachs analyst Tina Hou downgraded NIO from&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90, citing competitive pressures&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">and a difficult path to profitability ahead</a>.
The analyst notes NIO is unfavorably positioned heading into 2025 given the slow production ramp of&nbsp;Onvo and the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv" rel="noreferrer noopener">limited new model pipeline.</a>
Recently, NIO guided deliveries of 72,000–75,000 units for the fourth quarter, or a 43.9% –&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">49.9% year-over-year increase.&nbsp;</a>
The company expects&nbsp;fourth-quarter revenue&nbsp;of $2.804 billion – $2.904 billion, representing 15.0% – 19.2% year-over-year growth.
Price Action: NIO shares are trading higher by 2.55% to $4.410 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says" target="_blank" rel="noreferrer noopener">‘It's The Most Wonderful Time Of The Year' For The Stock Market, History Says</a></li>
</ul>
Photo via Shutterstock.

Markets

Movers

Media

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With Tesla's Chinese Rival NIO Stock Today?

William Blair analyst Sami Corwin has maintained their bullish stance on ALLO stock, giving a Buy rating yesterday. Sami Corwin's rating is based o...

Promising Efficacy and Strategic Advancements Propel Allogene Therapeutics to a Buy Rating

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a price ...

RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $10.0...

Oppenheimer Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Allogene Therapeutics (ALLO – Research Report). The associated price ta...

Promising Clinical Data and Strong Financial Position Reinforce Buy Rating for Allogene Therapeutics

In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report). The compa...

JMP Securities Remains a Hold on Allogene Therapeutics (ALLO)

William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given his ...

Strategic Resource Reallocation and Growth Focus Underpin Buy Rating for Allogene Therapeutics

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $9.00. T...

Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

Allogene Therapeutics (ALLO) announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluat...

Allogene Therapeutics presents data for ALLO-329 in autoimmune disease

JMP Securities analyst Reni Benjamin has maintained their neutral stance on ALLO stock, giving a Hold rating on November 11. Reni Benjamin's rating...

Cautious Hold Rating for Allogene Therapeutics Amid Promising Preclinical Data and Intense Competition

ALLO

MRNA

RNAC

Press Releases

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Management

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in November Investor Conferences

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Earnings

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Comments

Allogene Therapeutics

Notizie

Ultime notizie per Allogene Therapeutics (NASDAQ:ALLO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO